Exciting News: FDA Approves First Oral Therapy That Reduces Disease Activity For People With Relapsing MS

Earlier today the FDA approved oral fingolimod – brand name Gilenya (pronounced Jil-EN-ee-ah), a therapy produced and marketed by Novartis International AG. What this means is the first oral therapy to reduce disease activity in MS is expected to hit the market in a few weeks.

Click here to learn more about Gilenya and this exciting development in MS research and treatment.

Check out this news report on the FDA’s announcement, filmed Sept. 22 in our Dallas office:


Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out /  Change )

Google+ photo

You are commenting using your Google+ account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )


Connecting to %s